Axsome Therapeutics (AXSM) Enterprise Value (2015 - 2026)

Axsome Therapeutics has reported Enterprise Value for 12 years, with the latest figure at -$305.1 million in Q1 2026.

• Quarterly Enterprise Value fell 1.4% year-over-year to -$305.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$305.1 million (down 1.4% YoY) and the FY2025 annual result came in at -$322.9 million, down 2.4% from the prior year.
• Enterprise Value climbed to -$305.1 million in Q1 2026 per AXSM's latest filing, from -$322.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$73.4 million in Q2 2022 and troughed at -$437.1 million in Q2 2023.
• A 5-year average of -$289.4 million and a median of -$315.4 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 48.57% in 2022, then plunged 495.57% in 2023.
• Over 5 years, Enterprise Value stood at -$200.8 million in 2022, then sank by 92.29% to -$386.2 million in 2023, then gained by 18.34% to -$315.4 million in 2024, then fell by 2.4% to -$322.9 million in 2025, then rose by 5.52% to -$305.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$305.1 million, -$322.9 million, and -$325.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.